Literature DB >> 31646594

Propofol suppresses proliferation, migration and invasion of gastric cancer cells via regulating miR-29/MMP-2 axis.

Y-J Ni1, J Lu, H-M Zhou.   

Abstract

OBJECTIVE: Propofol (2,6-diisopropylphenol) is a commonly used intravenous anesthetic agent. Previous studies suggested that propofol might act as anti-tumor drug in various cancers, including gastric cancer. However, the underlying mechanism is still largely unknown.
MATERIALS AND METHODS: 1, 5, 10 and 20 μg/ml of propofol were used to treat gastric cancer cell MKN45 for 24, 48 or 72 hours. MTT assay was used to detect the proliferation. Transwell assay was employed to measure the invasion and migration with or without matrigel. The expression of miR-29a, 29b and 29c was assessed by quantitative real time polymerase chain reaction (qRT-PCR). Luciferase assay was introduced to confirm the relationship between miR-29 family member and MMP-2. Western blot was adopted to measure the expression of MMP-2 protein.
RESULTS: The proliferation, migration and invasion of gastric cancer cell MKN45 were gradually decreased after propofol treatment in time- and dose- dependent manners. MiR-29a, b and c were downregulated in MKN45 cells compared with normal gastric mucosa epithelial cell GES-1 and upregulated by propofol. Inhibition of miR-29a, b or c promoted cell proliferation, migration and invasion of MKN45 cells under propofol treatment. MMP-2 was a target and regulated by miR-29 family and propofol. MMP-2 silencing reversed the stimulative effects of miR-29 inhibitor.
CONCLUSIONS: Propofol inhibited cell proliferation, migration and invasion by upregulating miR-29a, miR-29b and miR-29c and downregulating MMP-2.

Entities:  

Year:  2019        PMID: 31646594     DOI: 10.26355/eurrev_201910_19177

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Dihydroartemisinin suppresses proliferation, migration, the Wnt/β-catenin pathway and EMT via TNKS in gastric cancer.

Authors:  Yanmei Ma; Peng Zhang; Qilong Zhang; Xiaofei Wang; Qiong Miao; Xiaolan Lyu; Bo Cui; Honghong Ma
Journal:  Oncol Lett       Date:  2021-07-29       Impact factor: 2.967

2.  A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity.

Authors:  Yufan Jian; Meina Zhao; Jinyi Cao; Tingting Fan; Wei Bu; Yang Yang; Weiwei Li; Wei Zhang; Yi Qiao; Jingwen Wang; Aidong Wen
Journal:  Drug Des Devel Ther       Date:  2020-06-12       Impact factor: 4.162

3.  Propofol inhibited gastric cancer proliferation via the hsa-miR-328-3p/STAT3 pathway.

Authors:  Z M Bai; X F Li; Y Yang; Y F Yang; D R Lv; L L Tang
Journal:  Clin Transl Oncol       Date:  2021-03-27       Impact factor: 3.405

Review 4.  Effects of propofol on the development of cancer in humans.

Authors:  Yichi Xu; Shuya Pan; Wenxiao Jiang; Fang Xue; Xueqiong Zhu
Journal:  Cell Prolif       Date:  2020-06-29       Impact factor: 6.831

5.  Activation of P2×7 Receptor Promotes the Invasion and Migration of Colon Cancer Cells via the STAT3 Signaling.

Authors:  Wen-Jun Zhang; Ce-Gui Hu; Hong-Liang Luo; Zheng-Ming Zhu
Journal:  Front Cell Dev Biol       Date:  2020-11-24

6.  Protective effect of propofol via the regulation of ovarian granulosa cell proliferation and apoptosis.

Authors:  Rong Ding; Wenyue Kang; Duozhi Wu; Lin Wang
Journal:  Exp Ther Med       Date:  2021-07-13       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.